Cargando…

The Effect of Disease Modifying Drugs of Multiple Sclerosis on the Effectiveness of BBIBP-CorV COVID19 Vaccine

Detalles Bibliográficos
Autores principales:	Ghaffari, Mehran, Beladimoghadam, Nahid, Aghamiri, Seyed Hossein, Haghighi, Mehrdad, Javadi, Abdolreza, Nahayati, Mohammadali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117605/ http://dx.doi.org/10.1016/j.msard.2022.103587

Ejemplares similares

BBIBP-CorV: Hepatitis: case report
Publicado: (2022)

BBIBP-CorV: Anterior uveitis: case report
Publicado: (2022)

Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
por: Jeewandara, Chandima, et al.
Publicado: (2022)

BBIBP-CorV: Steven-Johnson syndrome : case report
Publicado: (2022)

BBIBP-CorV: Acute disseminated encephalomyelitis: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson syndrome: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson-syndrome: case report
Publicado: (2022)

Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2023)

BBIBP-CorV/tozinameran: Subacute thyroiditis: 2 case reports
Publicado: (2022)

BBIBP-CorV: Adult multisystem inflammatory syndrome: case report
Publicado: (2021)

BBIBP-CorV: Eye disorders and hypertension: 7 case reports
Publicado: (2021)

Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals
por: Mallah, Saad I., et al.
Publicado: (2023)

BBIBP-CorV: Vaccine-induced immune thrombotic thrombocytopenia: case report
Publicado: (2022)

Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
por: Hosseinzadeh, Rezvan, et al.
Publicado: (2022)

Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka
por: Jeewandara, Chandima, et al.
Publicado: (2022)

Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV
por: Ali Sahraian, Mohammad, et al.
Publicado: (2021)

Abducense nerve palsy following BBIBP-CorV (Sinopharm) COVID-19 vaccine
por: Khalili, M.R., et al.
Publicado: (2022)

Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine
por: Tang, Bo, et al.
Publicado: (2022)

Cord blood antibodies following BBIBP‐CorV (Sinopharm) vaccination during pregnancy
por: Hantoushzadeh, Sedigheh, et al.
Publicado: (2023)

Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco
por: Zhang, Yaowen, et al.
Publicado: (2022)

Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021
por: Silva-Valencia, Javier, et al.
Publicado: (2023)

Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals
por: Jeewandara, Chandima, et al.
Publicado: (2021)

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
por: Rouco, Santiago Oviedo, et al.
Publicado: (2022)

Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old
por: Greish, Khaled, et al.
Publicado: (2022)

Autoimmune encephalitis after BBIBP-CorV (Sinopharm) COVID-19 vaccination: a case report
por: Vences, Miguel A., et al.
Publicado: (2022)

BBIBP-CorV Vaccination against the SARS-CoV-2 Virus Affects the Gut Microbiome
por: Shen, Yang, et al.
Publicado: (2023)

Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates
por: Al Kaabi, Nawal, et al.
Publicado: (2022)

Evaluation of SARS-CoV-2 Serum Level in Patients Vaccinated With Sinopharm/BBIBP-CorV With Kidney Transplantation
por: Rahbar, Maryam, et al.
Publicado: (2022)

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
por: Wang, Hui, et al.
Publicado: (2020)

SARS-CoV-2-specific T Cell Immunity after Vaccination with Sputnik V and BBIBP-CorV
por: Babrukevich, Darya, et al.
Publicado: (2022)

RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine
por: Ferenci, Tamás, et al.
Publicado: (2022)

Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study
por: Gómez de la Torre, Juan C., et al.
Publicado: (2022)

Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum
por: Zhu, Yuqi, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 omicron after BBIBP-CorV and ZF2001 booster vaccination
por: Zhang, Yuwei, et al.
Publicado: (2023)

SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study
por: Safarnezhad Tameshkel, Fahimeh, et al.
Publicado: (2023)

Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
por: Chansaenroj, Jira, et al.
Publicado: (2022)

Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort
por: Zamani, Batool, et al.
Publicado: (2023)

BBIBP-CorV/SARS-COV-2-vaccine-inactivated-Sinovac-Biotech: Eye disorders: 7 case reports
Publicado: (2022)

Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7go6rrbtk5r7delc6usedas6te